EMERYVILLE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) — Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced presentations at two upcoming investor conferences in August.
Karin Jooss, Ph.D., executive vice president of research and chief scientific officer, will present at the William Blair Biotech Focus Conference 2020 on Wednesday, August 5, 2020 at 2:25 p.m. ET.Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present at the BTIG Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 2:00 p.m. ET.A live webcast will be available within the Investors & Media section of the Gritstone Oncology website at https://ir.gritstoneoncology.com/investors/events. An archived replay will be accessible for 30 days following the event.About Gritstone Oncology
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—second, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to potentially drive the patient’s immune system to specifically attack and destroy tumors. The company’s individualized neoantigen-based immunotherapy, GRANITE, and its “off the shelf” shared neoantigen-based immunotherapy, SLATE, are being evaluated in clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone’s BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.Contacts
Media:
Dan Budwick
1AB
(973) 271-6085
[email protected]Investors:
Alexandra Santos
Wheelhouse Life Science Advisors
(510) 871-6161
[email protected]
Bay Street News
